Evotec SE - American Depositary Shares (EVO)

Q3 loss narrowed on cost cuts, and a new Vertex manufacturing win.

Evotec (NASDAQ:EVO) reported a narrower adjusted EBITDA loss for the third quarter of 2026 and reaffirmed its full-year guidance, saying it expects revenue and earnings to finish toward the upper ends of their respective ranges. The company said stronger commercial execution in its drug discovery a

Evotec (NASDAQ:EVO) reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements. Chief

Evotec (EVO) Q3 2025 Earnings Call Transcript

Evotec shares rise after joining NURTuRE-AKI to advance kidney disease research through molecular data integration.

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024.

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.